• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, July 5, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Preclinical characterization of therapeutic antibodies

Bioengineer by Bioengineer
March 12, 2018
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Bhairavi Tolani, email: [email protected] David M. Jablons, email: [email protected]

Even though the Shh pathway is mainly quiescent in adults, the safety of Shh-targeting with therapeutic antibodies was questioned initially because not only does the N-terminus of the Shh protein play an important role in embryonic development, but Shh also plays a poorly understood role in tissue homeostasis and repair in adults.

Furthermore, the research team previously showed that Shh+ cells expressing the full-length protein appeared to provide a signal for proliferation, migration and chemotherapy-resistance properties, making functional targeting of full-length Shh by the use of C-terminus anti-Shh antibodies an attractive therapeutic strategy.

Ex vivo analyses of A549 xenograft tumors from mice treated with the C-terminus Shh antibody Ab 1C11-2G4 provided further support that Shh signal transduction is modestly down-regulated after treatment, as evidenced by suppressed transcript and protein levels of Shh downstream target GLI. Activation of the pathway occurs when Shh binds to its receptor Patched but signaling is inhibited in a small population of cells if full-length Shh binds instead to the blocking antibody 2G4, a potential therapeutic, so that the protein cannot transmit downstream signals.

Another reason for the modest efficacy the research team observed could be that the antibody also binds cleaved C-terminus Shh produced by a majority of the cells, which has no known Shh signaling function, and which may deplete the amount of antibody available for therapeutic binding to cell-surface expressed full-length Shh.

The researchers said "Administration of Ab 1C11-2G4 not only reduced cell viability in 7 cancer cell lines but also significantly inhibited tumor growth in a xenograft model of A549 lung cancer cells."

When ectopically expressed, Shh triggers tumor formation in preclinical models, lending credence to the idea that ligand-dependent Shh pathway activation promotes tumor initiation and progression.

Targeting ligand-dependent Shh signaling with Smoothened antagonists or Shh neutralizing antibodies inhibits the growth of several tumor cell lines in vitro and in vivo.

While blocking the Shh pathway is an attractive anti-cancer strategy, no therapeutic antibody raised against the carboxy -terminal of the Shh protein has been described.

The researchers recently reported the presence of uncleaved, membrane-bound, full-length Shh on fresh primary lung tumors collected from patients and in cancer cell lines and have reported initial validation of this full-length protein as a novel marker of cancer stem cells (CSC) in NSCLC. These findings led them to hypothesize that antibodies generated against the C-terminus Shh epitope can bind and neutralize full-length Shh found exclusively on the CSC population, while leaving the cleaved N-terminus Shh, important for physiologic Shh signaling, unperturbed

###

Full text – http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=24510&path%5B%5D=76946

Correspondence to –

Bhairavi Tolani
email: [email protected]

David M. Jablons
email: [email protected]

About Oncotarget

Oncotarget is twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.

Media Contact

Ryan James Jessup
[email protected]
202-638-9720

Original Source

http://www.oncotarget.com/news/pr/preclinical-characterization-of-therapeutic-antibodies-targeted-at-the-carboxy-terminus-of-sonic-hedgehog

Share14Tweet8Share2ShareShareShare2

Related Posts

Chemical structure of Pep19

Peptide with anti-obesity action is successfully tested in animal trial

July 5, 2022
Infographic of Mosaic-8

Wellcome Leap announces breakthrough in funded project at Caltech – points to new all-in-one vaccine for SARS-like betacoronaviruses – Phase I clinical trials initiated by CEPI

July 5, 2022

USC researcher leads effort to improve research on diet and dementia

July 4, 2022

Researchers propose a new live-attenuated influenza A vaccine approach

July 4, 2022
Please login to join discussion

POPULAR NEWS

  • Pacific whiting

    Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    37 shares
    Share 15 Tweet 9
  • Telescopic contact lenses

    39 shares
    Share 16 Tweet 10
  • Emerging Omicron subvariants BA.2.12.1, BA.4 and BA.5 are inhibited less efficiently by antibodies

    37 shares
    Share 15 Tweet 9
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

WeaponryVehiclesVaccinesVirologyVirusUrogenital SystemUrbanizationUniversity of WashingtonWeather/StormsViolence/CriminalsVaccineZoology/Veterinary Science

Recent Posts

  • Robotic ammonites recreate ancient animals’ movements
  • 1930s ‘redlining’ connected to poor health outcomes today
  • Natural gas is key to WVU engineer’s vision for clean hydrogen energy
  • Neuroscientists to study effects of marijuana use during adolescence with $2M NIH grant
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....